Welcome to our dedicated page for Quidel SEC filings (Ticker: QDEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The QuidelOrtho Corporation (Nasdaq: QDEL) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As an issuer in the in vitro diagnostics and medical device manufacturing space, QuidelOrtho uses these filings to report on its financial condition, capital structure, material agreements and other significant events.
Investors can review current reports on Form 8‑K, where QuidelOrtho furnishes press releases announcing quarterly financial results, earnings conference calls and stockholder letters discussing recent performance and strategic priorities. For example, 8‑K filings in November 2025 reference third‑quarter results and a stockholder communication, while an August 21, 2025 8‑K details a Credit Agreement that established senior secured term loan A and term loan B facilities and a revolving credit facility with a syndicate of lenders.
Alongside 8‑Ks, users can also access annual reports on Form 10‑K and quarterly reports on Form 10‑Q, which provide more comprehensive information on QuidelOrtho’s business, including its diagnostic segments in clinical chemistry, immunoassay, immunohematology and molecular testing. These reports typically include discussions of risk factors, research and development spending, and other elements that shape the company’s long‑term outlook.
For those interested in governance and ownership, proxy statements and beneficial ownership reports (such as Forms 3, 4 and 5) can be used to analyze executive and director holdings and transactions, although specific examples are not detailed here. Together, these documents form a record of how QuidelOrtho communicates with regulators and investors about its operations and capital decisions.
Stock Titan enhances this information by pairing real‑time EDGAR updates with AI‑powered summaries that explain the key points of long filings in plain language. Users can quickly see what each new 10‑K, 10‑Q, 8‑K or Form 4 means for QuidelOrtho without reading every page, while still having direct access to the full text for deeper review.
QuidelOrtho Corp Chief Financial Officer Joseph M. Busky reported equity compensation activity involving restricted stock units and common shares. On February 8, 2026, 5,968 restricted stock units were converted into 5,968 shares of common stock at a stated price of $0.
In connection with this release, 1,806 common shares at $29.1 per share were withheld by the issuer to satisfy tax withholding obligations, leaving Busky with 41,412 common shares held directly. He also reports 6,920 common shares held indirectly by a trust.
The filing notes that 5,968 shares vested on each of February 8, 2025 and February 8, 2026, and 5,969 additional shares are scheduled to vest on February 8, 2027, reflecting an ongoing multi‑year restricted stock unit vesting schedule.
QuidelOrtho Corporation reported that board member Matthew W. Strobeck has decided not to stand for re-election at the company’s 2026 annual stockholders meeting. He will remain on the board until that meeting, after which the board size will decrease from eleven to ten directors. The company states that his decision is due to other professional commitments and not any dispute or disagreement with the company, its board, or management over operations, policies, or practices.
FMR LLC filed an amended Schedule 13G reporting beneficial ownership of 5,420,217.85 shares of QuidelOrtho Corp common stock, representing 8.0% of the class as of the event date. FMR has sole voting power over 5,416,389 shares and sole dispositive power over 5,420,217.85 shares.
Abigail P. Johnson is also reported as a beneficial owner of 5,420,217.85 shares, with sole dispositive power and no voting power. The filers state the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of QuidelOrtho.
The filing notes that one or more other persons may receive dividends or sale proceeds from these shares, but no such person has an interest exceeding five percent of QuidelOrtho’s outstanding common stock.
QuidelOrtho Corporation’s Chief Human Resources Officer, Ronald Lee Bowman, reported equity awards on January 30, 2026. He received 36,152 restricted stock units, each representing one share of common stock, and 36,150 non-qualified stock options with a $27.17 exercise price expiring January 30, 2036.
Of the restricted stock units, 12,050 shares will vest on January 30, 2027, and the remaining 24,102 shares will vest in equal installments on January 30, 2028 and January 30, 2029. The 36,150 stock options will vest in equal installments on January 30, 2027, January 30, 2028 and January 30, 2029. All holdings are reported as directly owned.
QuidelOrtho Corp Chief Operations Officer Philip D. McLellan reported multiple equity compensation transactions. On January 30, 2026, he received 36,152 restricted stock units and 36,150 non-qualified stock options with a $27.17 exercise price, vesting in tranches from 2027 to 2029. On January 31, 2026, several blocks of restricted stock units converted into common stock, increasing his direct holdings, while the company withheld shares at $27.17 per share to cover tax obligations. After these transactions, he directly owned 19,174 shares of common stock, plus the newly granted RSUs and options.
QuidelOrtho Corporation executive Jonathan Philip Siegrist, EVP of R&D & CTO, reported new equity awards in the form of restricted stock units (RSUs) and stock options. On January 30, 2026, he received 36,152 RSUs, each representing one share of QuidelOrtho common stock, and 36,150 non-qualified stock options with a $27.17 exercise price.
For the RSUs, 12,050 shares are scheduled to vest on January 30, 2027, and the remaining 24,102 shares will vest in equal installments on January 30, 2028 and January 30, 2029. The 36,150 stock options will vest in equal installments on January 30, 2027, January 30, 2028 and January 30, 2029. All awards are reported as directly owned by Siegrist.
QuidelOrtho Corporation’s Chief Legal Officer, Michelle A. Hodges, reported multiple equity transactions. On January 30, 2026, she received 38,562 restricted stock units (RSUs) and 38,561 non-qualified stock options with an exercise price of $27.17, with vesting scheduled between 2027 and 2029 and the options expiring in 2036.
On January 31, 2026, previously granted RSUs for 1,610 and 1,814 shares converted into the same number of common shares at no cost. The company withheld 578 and 651 shares at $27.17 per share to cover tax obligations. After these transactions, she directly held 39,555 shares of common stock.
QuidelOrtho Corporation reported an equity compensation grant to its Chief Financial Officer, Joseph M. Busky. On January 30, 2026, he was awarded 29,444 restricted stock units (RSUs), each representing one share of QuidelOrtho common stock, at a grant price of $0 as part of his compensation.
According to the vesting schedule, 9,814 shares will vest on January 30, 2027. The remaining 19,630 shares will vest in equal installments on January 30, 2028 and January 30, 2029, aligning Busky’s incentives with the company’s multi‑year performance.
QuidelOrtho Corporation President and CEO Brian J. Blaser received a grant of 213,470 restricted stock units on January 30, 2026. Each unit represents the right to receive one share of QuidelOrtho common stock.
According to the vesting schedule, 71,156 shares will vest on January 30, 2027. The remaining 142,314 shares will vest in equal installments on January 30, 2028 and January 30, 2029, aligning the CEO’s compensation with longer-term company performance.
QuidelOrtho Corporation executive Jonathan Philip Siegrist, EVP of R&D & CTO, reported equity compensation activity involving restricted stock units and common shares. On January 29, 2026, 2,448 restricted stock units vested and converted into the same number of QuidelOrtho common shares at $0 per share.
To cover tax withholding on this vesting, 1,009 common shares were disposed of at a price of $27.41 per share through share withholding. After these transactions, Siegrist directly owned 13,419 common shares and held 4,898 restricted stock units, which are scheduled to vest in equal installments on January 29, 2027 and January 29, 2028.